New drug duo aims to shrink stomach tumors before surgery
NCT ID NCT07315035
First seen Jan 08, 2026 · Last updated May 01, 2026 · Updated 15 times
Summary
This study tests whether adding an experimental immunotherapy drug (QL1706) to standard chemotherapy before surgery can improve outcomes for people with a certain type of stomach cancer. About 74 adults aged 18-75 with stage 3 diffuse-type gastric cancer will be randomly assigned to receive either the drug combo or chemo alone, followed by surgery. The main goal is to see if the combination leads to a complete disappearance of cancer cells in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.